New DHE-led study on the cost-effectiveness of pramipexole augmentation for acute phase and maintenance treatment of treatment-resistant depression is published in The Lancet Regional Health - Europe.
The cost-effectiveness analysis was conducted alongside the PAX-D randomized controlled trial, evaluating pramipexole augmentation for the acute and maintenance treatment of patients with treatment-resistant depression (TRD) in the UK. The study showed that pramipexole augmentation is a cost-effective option compared to placebo. From a health and social care perspective, pramipexole was associated with greater health gains at somewhat higher costs resulting in incremental cost-effectiveness ratios well below the £20,000 per QALY threshold. From a societal perspective, pramipexole was found to be more effective and less costly than placebo due to reductions in work absenteeism and informal care need. Findings support the implementation of pramipexole as augmentation treatment for TRD.
Click here for the publication.